戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 red immune responses to both live vector and heterologous antigen.
2 the vector would not limit expression of the heterologous antigen.
3 ease-causing meningococci expressing vaccine-heterologous antigens.
4  the homologous antigens than those with the heterologous antigens.
5 oliferation in response to both parasite and heterologous antigens.
6 d are being developed as vaccine vectors for heterologous antigens.
7 homologous strains but only a 70K band using heterologous antigens.
8  a vector for the expression and delivery of heterologous antigens.
9 cessfully to improve immune responses toward heterologous antigens.
10 ped as vaccine vectors for the expression of heterologous antigens.
11 ease-causing meningococci expressing vaccine-heterologous antigens.
12 accines, as cloning hosts and as carriers of heterologous antigens.
13  imparting "second site" interactions toward heterologous antigens.
14 o induce antibody responses to the expressed heterologous antigen after oral or intranasal immunizati
15 es expression of virulence genes and encoded heterologous antigens (Ags) in appropriately engineered
16 ne response against both the live vector and heterologous antigen and, as occurs following oral inocu
17 ic IgGs could react to homologous as well as heterologous antigens and parasites, suggesting that con
18  vector strains to effect secretion of large heterologous antigens and that a V. cholerae vector stra
19 ngendering immune responses against both the heterologous antigens and vector strain.
20  and may provide a means by which to deliver heterologous antigens and/or immune modulators of the in
21 esented and processed in a manner similar to heterologous antigen, and with differences in the mechan
22  associated with impaired immune response to heterologous antigens, and that antiviral therapy may am
23 their variable domain to express epitopes of heterologous antigens-antigenized antibodies-function as
24  studies on RASV development differ on where heterologous antigens are expressed and localized within
25 e optimal promoter for in vivo expression of heterologous antigens by live, attenuated vaccine vector
26 optimal protective immunity to homologous or heterologous antigens by oral, intranasal, or intraperit
27 r the regulated delayed in vivo synthesis of heterologous antigens by vaccine strains.
28   However, synthesis of sufficient levels of heterologous antigen can result in an increase in metabo
29 ng, including live vector systems expressing heterologous antigens, conjugation of antigen to carrier
30 d to generate beneficial immune responses to heterologous antigens during sustained pharyngeal carria
31         Memory B cells (MBCs) can respond to heterologous antigens either by molding new specificitie
32                                        Thus, heterologous antigen exposure or ST2-signaling can drive
33       In this study, the benefit of having a heterologous antigen expressed on the surface of a live
34 detect immune responses directed against the heterologous antigens expressed at low levels in any gro
35 ion and immunization, including responses to heterologous antigens expressed by cholera vector strain
36 hown by the induction of T cell responses to heterologous antigens expressed by RhCMV lacking the gen
37 ttenuated vaccine strains or as vehicles for heterologous antigen expression.
38 nto host cells, have been adapted to deliver heterologous antigens for vaccine development.
39 vector (BRD509) to immunize mice against the heterologous antigen fragment C (FrgC).
40                                Expression of heterologous antigens from rVSV vectors has demonstrated
41                           Sheaths displaying heterologous antigens generated better immune responses
42  mutation in a Salmonella vaccine to deliver heterologous antigens has not yet been investigated.
43  immune responses directed against expressed heterologous antigens have been developed.
44  stomatitis virus (VSV) vectors that express heterologous antigens have shown promise as vaccines in
45 ials of S. enterica serovar Typhi expressing heterologous antigens have shown that few subjects have
46                 We proposed that coupling of heterologous antigens improves antibody responses across
47 icited effective priming of CD8 T cells to a heterologous antigen in mice.
48 uced a specific immune response against this heterologous antigen in mice.
49 ) autotransporter system for accumulation of heterologous antigens in cell culture supernatant.
50  been developed that allow the expression of heterologous antigens in commensal Gram-positive bacteri
51 arantee the OMV compartmentalization of most heterologous antigens in quantities high enough to elici
52 expression from plasmids of at least certain heterologous antigens in such strains.
53 two strains contain genes encoding different heterologous antigens in the chromosome of the vaccine v
54                     And that the location of heterologous antigens in the subcellular components of g
55  a novel export system for the expression of heterologous antigens in the supernatant of attenuated S
56 ental antigens and cytokines released during heterologous, antigen-independent immune responses is cu
57 dings confirm that vaccination strategy with heterologous antigens might be a good option to protect
58       We developed means to deliver multiple heterologous antigens on dual plasmids with non-antibiot
59 ng their effects on the immune response to a heterologous antigen, ovalbumin.
60 ed in the presence of autologous, as well as heterologous, antigen-presenting cells, suggesting a MHC
61 IFN-gamma(+) and CD8(+)IFN-gamma(+) cells by heterologous antigen recall.
62 Live attenuated bacterial strains expressing heterologous antigens represent an attractive vaccine de
63 tibody responses were stimulated to both the heterologous antigen rPspA and Salmonella lipopolysaccha
64 d to compare the immune responses to the two heterologous antigens, StxB1 and EaeA, expressed by thes
65 nally, recombinant DeltaNSs viruses encoding heterologous antigens, such as ovalbumin (OVA) or type-s
66 been used extensively to express and deliver heterologous antigens to host mucosal tissues.
67 lts demonstrate the possibility of targeting heterologous antigens to specific cellular compartments
68 n to be functional and capable of delivering heterologous antigens to the class I antigen presentatio
69 lla typhi vaccine strain CVD 908 can deliver heterologous antigens to the host immune system followin
70  (CPDs) are known to ferry covalently linked heterologous antigens to the intracellular compartment b
71 rains is a promising strategy for presenting heterologous antigens to the mammalian immune system to
72 bility of live Salmonella vectors to deliver heterologous antigens to the mammalian immune system.
73 d IgG2a pattern was observed for the carried heterologous antigen, which displayed a dominant IgG1 re
74             Thus, subsequent challenges with heterologous antigens, which themselves induce memory CT
75 r findings show that a strategy of combining heterologous antigen with self-antigens could produce a